Karyopharm Therapeutics traded at $1.62 this Friday September 25th, decreasing $0.11 or 6.36 percent since the previous trading session. Looking back, over the last four weeks, Karyopharm Therapeutics lost 17.35 percent. Over the last 12 months, its price fell by 75.27 percent. Looking ahead, we forecast Karyopharm Therapeutics to be priced at 1.84 by the end of this quarter and at 1.72 in one year, according to Trading Economics global macro models projections and analysts expectations.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.